RAFAEL HOLDINGS, INC. Accretion Expense
RAFAEL HOLDINGS, INC. (RFL) reported Accretion Expense of $85.00 thousand for the 9-month period ending 2024-04-30, per its 10-Q filed 2025-06-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2025-06-11
- 2024-04-30: Accretion Expense 9 month $85.00K.
| Period end | Accretion Expense 9 month |
|---|---|
| 2024-04-30 | $85.00K 10-Q · filed 2025-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |